Information Provided By:
Fly News Breaks for November 17, 2015
AZN, CLVS
Nov 17, 2015 | 05:37 EDT
Goldman Sachs analyst Terence Flynn downgraded Clovis Oncology (CLVS) to Neutral from Conviction Buy citing limited visibility on the path to FDA approval following yesterday's update on the company's lung cancer drug Roci. The drug now has a less compelling profile relative to AstraZeneca's (AZN) Tagrisso, Flynn tells investors in a research note. He cut his price target for shares to $23 from $123. Clovis closed yesterday down $66.19, or 70%, to $30.24.
News For CLVS;AZN From the Last 2 Days
AZN
Mar 18, 2024 | 08:17 EDT
Checkpoint Therapeutics (CKPT) announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca (AZN) Rare Disease.